Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 06, 2017 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the company will be participating in two upcoming investor conferences.
- Cowen 37th Annual Health Care Conference, March 6-8, 2017, Boston, MA
- Barclays Global Healthcare Conference, March 14-16, 2017, Miami, FL
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, Canada with facilities in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.
Contact Information Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604.419.3200 Email: [email protected] Media Please direct all media inquiries to: [email protected]
